方法对比
并排查看您选择的方法；存在差异的行会高亮显示。
| 第四期研究× | III期临床试验× | |
|---|---|---|
| 领域 | 流行病学 | 流行病学 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | Formalised 1970s–1990s (ICH E3 guideline 1994) | 1962 (Kefauver-Harris Amendment formalised phased drug development) |
| 提出者≠ | Regulatory agencies and pharmaceutical industry (ICH, FDA, EMA frameworks) | FDA regulatory framework / ICH guidelines |
| 类型≠ | Post-marketing observational or interventional study | Confirmatory randomised controlled trial |
| 开创性文献≠ | International Conference on Harmonisation (ICH). (1994). ICH Harmonised Tripartite Guideline: Structure and Content of Clinical Study Reports E3. ICH Secretariat. link ↗ | Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015). Fundamentals of Clinical Trials (5th ed.). Springer. ISBN: 978-3319185385 |
| 别名 | post-marketing surveillance study, post-approval study, Phase 4 study, PMS study | Phase 3 trial, confirmatory trial, pivotal trial, Phase III RCT |
| 相关≠ | 5 | 6 |
| 摘要≠ | A Phase IV study is a post-marketing surveillance study conducted after a drug, device, or intervention has received regulatory approval. Its primary purpose is to monitor long-term safety, detect rare adverse events, assess effectiveness in routine clinical practice, and explore new indications or populations not adequately represented in earlier trials. Phase IV evidence accumulates continuously throughout a product's commercial life. | A Phase III clinical trial is a large-scale, confirmatory randomised controlled trial designed to establish the efficacy and safety of an intervention in the target patient population before regulatory submission. It builds on the signal identified in Phase II, tests the intervention at its proposed dose under controlled conditions, and provides the primary evidence base for marketing authorisation or guideline adoption. |
| ScholarGate数据集 ↗ |
|
|